Protalix Investigated for Securities Violations by Schall Law Firm.

The Schall Law Firm is investigating Protalix BioTherapeutics for potential securities law violations. The investigation focuses on whether the company issued false or misleading statements and/or failed to disclose information pertinent to investors. Protalix and Chiesi Global Rare Diseases received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on the request to approve the dosing regimen for Elfabrio.